|本期目录/Table of Contents|

[1]刘 嘉,刘 彤.应用XELOX及FOLFOX4方案治疗进展期胃癌疗效及安全性评价[J].天津医科大学学报,2015,21(02):140-142.
　LIU Jia,LIU Tong.Curative effect and safety assessment of XELOX and FOLFOX4 chemotherapy regimens for patients with advanced gastric cancer[J].Journal of Tianjin Medical University,2015,21(02):140-142.
点击复制

应用XELOX及FOLFOX4方案治疗进展期胃癌疗效及安全性评价(PDF)
分享到：

《天津医科大学学报》[ISSN:1006-8147/CN:12-1259/R]

卷:
21卷
期数:
2015年02期
页码:
140-142
栏目:
临床医学
出版日期:
2015-03-20

文章信息/Info

Title:
Curative effect and safety assessment of XELOX and FOLFOX4 chemotherapy regimens for patients with advanced gastric cancer
文章编号:
1006-8147（2015）02-0140-03
作者:
刘 嘉; 刘 彤
(天津医科大学总医院普通外科,天津 300052)
Author(s):
LIU Jia;  LIU Tong
(Department of General Surgery, General Hospital, Tianjin Medical University, Tianjin 300052, China)
关键词:
进展期胃癌; 奥沙利铂联合卡培他滨 ; 奥沙利铂、亚叶酸钙联合氟尿嘧啶; 疗效; 安全性
Keywords:
advanced gastric cancer;  XELOX;  FOLFOX4; curative efficacy;  safety
分类号:
R735.2
DOI:
-
文献标志码:
A
摘要:
目的：比较奥沙利铂联合卡培他滨（XELOX方案）与奥沙利铂、亚叶酸钙联合氟尿嘧啶（FOLFOX4方案）治疗进展期胃癌的疗效及安全性。方法：58例进展期胃癌患者分别采用XELOX及FOLFOX4方案进行化疗，化疗后比较两组的临床疗效，包括血清肿瘤标记物浓度及不良反应发生率。结果：在临床有效方面，接受XELOX方案化疗组有效率更高，与接受FOLFOX4方案化疗组比较具有统计学差异（P＜0.05）；两组在化疗后血清肿瘤标记物浓度值较化疗前均有所下降，两组间比较无统计学差异（P＞0.05）。在不良反应发生率方面，应用XELOX方案化疗组胃肠道反应发生率明显低于应用FOLFOX4方案化疗组，其差异具有统计学意义（P＜0.05。在骨髓抑制、肝肾功能损害及神经毒性发生率方面，两化疗方案无显著统计学差异（P＞0.05）。结论：对于进展期胃癌的治疗，XELOX方案较FOLFOX4方案疗效更好，安全性更高。
Abstract:
Objective: To compare the effects and safety of XELOX and FOLFOX4 chemotherapy regimens in the treatment of patients with advanced gastric cancer. Methods： Fifty-eight patients with advanced gastric cancer were were treated with XELOX and FOLFOX4 chemotherapy respectively. The clinical efficacy , the concentration of the various tumor makers and safety were compared. Results：Compared with the group of FOLFOX4, the group of XELOX showed much better clinical effects, with significant statistical difference (P<0.05). The serum tumor marker concentration of the two groups was decreased after the neoadjuvant chemotherapy and no significant difference between the two groups was found（P＞0.05）. For the adverse reactions, the incidence of the gastrointestinal reactions showedsignificant difference(P<0.05) between the two groups, with lower reactions in the group of XELOX; and no significant differences in the incidence of bone marrow depressions, hepatic and renal functional lesion and neurotoxicity were discovered. Conclusion：In the treatment of advanced gastric cancer, the XELOX chemotherapy regimen is more effective with higher safety than FOLFOX4 chemotherapy.

参考文献/References:

[1]郭卫红,宋宏先,尚飞燕.胃癌患者血清肿瘤坏死因子-α及肿瘤坏死因子可溶性受体Ⅰ检测意义[J].山西医药杂志,2011,40(3):244
[2]王海鹏,田小林.不同化疗方案治疗晚期胃癌的疗效及安全性评价[J].广西医学,2010,32(3):287
[3]孙震,杨肖军,程伏林,等.新辅助化疗FOLFOX4方案治疗进展期胃癌的临床疗效[J].肿瘤防治研究,2014,41(7):803
[4]郑积华,周娟,谢波,等.不同化疗方案治疗老年晚期胃癌患者的疗效和安全性比较[J].实用医学杂志,2014,30(13):2086
[5]陈柏芳.不同化疗方案治疗胃癌的临床研究[J].中国医药导报,2011,8(24):30
[6]陈静,林源,段玉琴,等.不同化疗方案治疗老年晚期胃癌的临床研究[J].中国基层医药,2010,17(17):2365
[7]张瑞雪,闫涵,王民,等.XELOX方案与FOLFOXs方案治疗中国晚期胃癌患者的Meta分析[J].首都医科大学学报,2013,34(3):422

相似文献/References:

备注/Memo

备注/Memo:

作者简介 刘嘉(1983-)，男，主治医师，硕士在读， 研究方向：胃肠外科；

通信作者：刘彤， E-mail ：liutonga@126.com。

 

更新日期/Last Update: 2015-03-24